Cargando…
microRNA Expression and Its Association With Disability and Brain Atrophy in Multiple Sclerosis Patients Treated With Glatiramer Acetate
BACKGROUND: MicroRNAs are small non-coding RNA that regulate gene expression at a post-transcriptional level affecting several cellular processes including inflammation, neurodegeneration and remyelination. Different patterns of miRNAs expression have been demonstrated in multiple sclerosis compared...
Autores principales: | Dominguez-Mozo, María I., Casanova, Ignacio, De Torres, Laura, Aladro-Benito, Yolanda, Perez-Perez, Silvia, Garcia-Martínez, Angel, Gomez, Patricia, Abellan, Sara, De Antonio, Esther, Lopez-De-Silanes, Carlos, Alvarez-Lafuente, Roberto |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9239306/ https://www.ncbi.nlm.nih.gov/pubmed/35774792 http://dx.doi.org/10.3389/fimmu.2022.904683 |
Ejemplares similares
-
MicroRNAs Associated with Disability Progression and Clinical Activity in Multiple Sclerosis Patients Treated with Glatiramer Acetate
por: Casanova, Ignacio, et al.
Publicado: (2023) -
Acetate correlates with disability and immune response in multiple sclerosis
por: Pérez-Pérez, Silvia, et al.
Publicado: (2020) -
Glatiramer acetate in the treatment of multiple sclerosis
por: Tselis, Alex, et al.
Publicado: (2007) -
Brain Atrophy Rates for Stable Multiple Sclerosis Patients on Long-Term Fingolimod versus Glatiramer Acetate
por: Honce, Justin M., et al.
Publicado: (2020) -
Adherence to glatiramer acetate treatment for multiple sclerosis: the Brazilian experience
por: de Oliveira, Tatiana de Melo Gomes, et al.
Publicado: (2008)